Here’s What’s Next
Novavax (NVAX) had fallen behind in the race to get a Covid-19 vaccine to market and watched as others gained approval and made successful market entries with their respective offerings. However, last week Novavax finally released the data for its U.S./Mexico late-stage trials and the results were excellent, placing the biotech in the same league as its rivals.
The trial’s success is the third such study Novavax’s Covid-19 vaccine candidate NVX-CoV2373 has excelled at following successful tests in the U.K. and South Africa.
B. Riley’s Mayank Mamtani thinks that going forward this factor could give Novavax an edge not only because of the diverse trial locations but also due to it proving effective in “a variant-rich environment.”
“With three successful large-scale studies executed across different geographies in North America, Europe & Africa, NVAX has accumulated an extensive body of evidence supportive of NVX-CoV2373 as the C-19 vaccine candidate generating the highest VE, i.e., 90%+, against circulating variants, particularly VOC/ VOI,” the 5-star analyst opined.
Novavax might have been late to the initial vaccination race, but in the anticipated booster market, Mamtani thinks “the safety profile of ‘2373 is particularly attractive.”